Cargando…
Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
Executive function is an umbrella term that includes cognitive processes such as decision-making, impulse control, attention, behavioral flexibility, and working memory. Each of these processes depends largely upon monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams and Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155367/ https://www.ncbi.nlm.nih.gov/pubmed/30215621 http://dx.doi.org/10.1097/FBP.0000000000000430 |
_version_ | 1783357886614732800 |
---|---|
author | Ozga, Jenny E. Povroznik, Jessica M. Engler-Chiurazzi, Elizabeth B. Haar, Cole Vonder |
author_facet | Ozga, Jenny E. Povroznik, Jessica M. Engler-Chiurazzi, Elizabeth B. Haar, Cole Vonder |
author_sort | Ozga, Jenny E. |
collection | PubMed |
description | Executive function is an umbrella term that includes cognitive processes such as decision-making, impulse control, attention, behavioral flexibility, and working memory. Each of these processes depends largely upon monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in the frontal cortex, striatum, and hippocampus, among other brain areas. Traumatic brain injury (TBI) induces disruptions in monoaminergic signaling along several steps in the neurotransmission process – synthesis, distribution, and breakdown – and in turn, produces long-lasting deficits in several executive function domains. Understanding how TBI alters monoamingeric neurotransmission and executive function will advance basic knowledge of the underlying principles that govern executive function and potentially further treatment of cognitive deficits following such injury. In this review, we examine the influence of TBI on the following measures of executive function – impulsivity, behavioral flexibility, and working memory. We also describe monoaminergic-systems changes following TBI. Given that TBI patients experience alterations in monoaminergic signaling following injury, they may represent a unique population with regard to pharmacotherapy. We conclude this review by discussing some considerations for pharmacotherapy in the field of TBI. |
format | Online Article Text |
id | pubmed-6155367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams and Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-61553672018-10-12 Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology Ozga, Jenny E. Povroznik, Jessica M. Engler-Chiurazzi, Elizabeth B. Haar, Cole Vonder Behav Pharmacol Review Articles Executive function is an umbrella term that includes cognitive processes such as decision-making, impulse control, attention, behavioral flexibility, and working memory. Each of these processes depends largely upon monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in the frontal cortex, striatum, and hippocampus, among other brain areas. Traumatic brain injury (TBI) induces disruptions in monoaminergic signaling along several steps in the neurotransmission process – synthesis, distribution, and breakdown – and in turn, produces long-lasting deficits in several executive function domains. Understanding how TBI alters monoamingeric neurotransmission and executive function will advance basic knowledge of the underlying principles that govern executive function and potentially further treatment of cognitive deficits following such injury. In this review, we examine the influence of TBI on the following measures of executive function – impulsivity, behavioral flexibility, and working memory. We also describe monoaminergic-systems changes following TBI. Given that TBI patients experience alterations in monoaminergic signaling following injury, they may represent a unique population with regard to pharmacotherapy. We conclude this review by discussing some considerations for pharmacotherapy in the field of TBI. Lippincott Williams and Wilkins 2018-10 2018-09-14 /pmc/articles/PMC6155367/ /pubmed/30215621 http://dx.doi.org/10.1097/FBP.0000000000000430 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Review Articles Ozga, Jenny E. Povroznik, Jessica M. Engler-Chiurazzi, Elizabeth B. Haar, Cole Vonder Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
title | Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
title_full | Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
title_fullStr | Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
title_full_unstemmed | Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
title_short | Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
title_sort | executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155367/ https://www.ncbi.nlm.nih.gov/pubmed/30215621 http://dx.doi.org/10.1097/FBP.0000000000000430 |
work_keys_str_mv | AT ozgajennye executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology AT povroznikjessicam executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology AT englerchiurazzielizabethb executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology AT haarcolevonder executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology |